메뉴 건너뛰기




Volumn 51, Issue 9, 2015, Pages 549-558

Talimogene laherparepvec (T-VEC) as cancer immunotherapy

Author keywords

Cancer immunotherapy; Melanoma; Oncolytic virus; OncoVEXGM CSF; Talimogene laherparepvec

Indexed keywords

ATEZOLIZUMAB; CISPLATIN; DABRAFENIB; IPILIMUMAB; NIVOLUMAB; TALIMOGENE LAHERPAREPVEC; ONCOLYTIC VIRUS;

EID: 84944745160     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2015.51.9.2383044     Document Type: Article
Times cited : (28)

References (40)
  • 1
    • 0037295403 scopus 로고    scopus 로고
    • ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
    • Liu, B.L., Robinson, M., Han, Z.Q. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003, 10(4): 292-303.
    • (2003) Gene Ther , vol.10 , Issue.4 , pp. 292-303
    • Liu, B.L.1    Robinson, M.2    Han, Z.Q.3
  • 2
    • 84933586864 scopus 로고    scopus 로고
    • Talimogene laherparepvec improves durable response ate in patients with advanced melanoma
    • Andtbacka, R.H., Kaufman, H.L., Collichio, F. et al. Talimogene laherparepvec improves durable response ate in patients with advanced melanoma. J Clin Oncol 2015, 33(25): 2780-8.
    • (2015) J Clin Oncol , vol.33 , Issue.25 , pp. 2780-2788
    • Andtbacka, R.H.1    Kaufman, H.L.2    Collichio, F.3
  • 3
    • 77149141965 scopus 로고    scopus 로고
    • Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    • Kaufman, H.L., Kim, D.W., DeRaffele, G., Mitcham, J., Coffin, R.S., Kim-Schulze, S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010, 17(3): 718-30.
    • (2010) Ann Surg Oncol , vol.17 , Issue.3 , pp. 718-730
    • Kaufman, H.L.1    Kim, D.W.2    DeRaffele, G.3    Mitcham, J.4    Coffin, R.S.5    Kim-Schulze, S.6
  • 4
    • 33845336115 scopus 로고    scopus 로고
    • A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colonystimulating factor
    • Hu, J.C., Coffin, R.S., Davis, C.J. et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colonystimulating factor. Clin Cancer Res 2006, 12(22): 6737-47.
    • (2006) Clin Cancer Res , vol.12 , Issue.22 , pp. 6737-6747
    • Hu, J.C.1    Coffin, R.S.2    Davis, C.J.3
  • 6
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman, P.B., Hauschild, A., Robert, C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26): 2507-16.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 7
    • 84868224906 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    • Flaherty, K.T., Infante, J.R., Daud, A. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367(18): 1694-703.
    • (2012) N Engl J Med , vol.367 , Issue.18 , pp. 1694-1703
    • Flaherty, K.T.1    Infante, J.R.2    Daud, A.3
  • 8
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman, J.A., Kim, K.B., Schuchter, L. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8): 707-14.
    • (2012) N Engl J Med , vol.366 , Issue.8 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 9
    • 84862908526 scopus 로고    scopus 로고
    • RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
    • Oberholzer, P.A., Kee, D., Dziunycz, P. et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012, 30(3): 316-21.
    • (2012) J Clin Oncol , vol.30 , Issue.3 , pp. 316-321
    • Oberholzer, P.A.1    Kee, D.2    Dziunycz, P.3
  • 10
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8): 711-23.
    • (2010) N Engl J Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 11
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert, C., Thomas, L., Bondarenko, I. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26): 2517-26.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 12
    • 3242677686 scopus 로고    scopus 로고
    • PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
    • Latchman, Y.E., Liang, S.C., Wu, Y. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004, 101(29): 10691-6.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , Issue.29 , pp. 10691-10696
    • Latchman, Y.E.1    Liang, S.C.2    Wu, Y.3
  • 13
    • 84929481481 scopus 로고    scopus 로고
    • Pembrolizumab versus ipilimumab in advanced melanoma
    • Robert, C., Schachter, J., Long, G.V. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015, 372(26): 2521-32.
    • (2015) N Engl J Med , vol.372 , Issue.26 , pp. 2521-2532
    • Robert, C.1    Schachter, J.2    Long, G.V.3
  • 14
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Hamid, O., Robert, C., Daud, A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369(2): 134-44.
    • (2013) N Engl J Med , vol.369 , Issue.2 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3
  • 15
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • Wolchok, J.D., Kluger, H., Callahan, M.K. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2): 122-33.
    • (2013) N Engl J Med , vol.369 , Issue.2 , pp. 122-133
    • Wolchok, J.D.1    Kluger, H.2    Callahan, M.K.3
  • 16
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer, J.R., Tykodi, S.S., Chow, L.Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26): 2455-65.
    • (2012) N Engl J Med , vol.366 , Issue.26 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 17
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 blockade in tumors with mismatch-repair deficiency
    • Le, D.T., Uram, J.N., Wang, H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015, 372(26): 2509-20.
    • (2015) N Engl J Med , vol.372 , Issue.26 , pp. 2509-2520
    • Le, D.T.1    Uram, J.N.2    Wang, H.3
  • 18
    • 84927150740 scopus 로고    scopus 로고
    • Immune checkpoint blockade in cancer therapy
    • Postow, M.A., Callahan, M.K., Wolchok, J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015, 33(17): 1974-82.
    • (2015) J Clin Oncol , vol.33 , Issue.17 , pp. 1974-1982
    • Postow, M.A.1    Callahan, M.K.2    Wolchok, J.D.3
  • 19
    • 0030807896 scopus 로고    scopus 로고
    • The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34
    • Brown, S.M., MacLean, A.R., McKie, E.A., Harland, J. The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34. J Virol 1997, 71(12): 9442-9.
    • (1997) J Virol , vol.71 , Issue.12 , pp. 9442-9449
    • Brown, S.M.1    MacLean, A.R.2    McKie, E.A.3    Harland, J.4
  • 20
    • 0042530129 scopus 로고    scopus 로고
    • The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins
    • Harland, J., Dunn, P., Cameron, E., Conner, J., Brown, S.M. The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins. J Neurovirol 2003, 9(4): 477-88.
    • (2003) J Neurovirol , vol.9 , Issue.4 , pp. 477-488
    • Harland, J.1    Dunn, P.2    Cameron, E.3    Conner, J.4    Brown, S.M.5
  • 21
    • 0030793170 scopus 로고    scopus 로고
    • Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: Failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene
    • He, B., Chou, J., Brandimarti, R., Mohr, I., Gluzman, Y., Roizman, B. Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997, 71(8): 6049-54.
    • (1997) J Virol , vol.71 , Issue.8 , pp. 6049-6054
    • He, B.1    Chou, J.2    Brandimarti, R.3    Mohr, I.4    Gluzman, Y.5    Roizman, B.6
  • 22
    • 0035902471 scopus 로고    scopus 로고
    • Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells
    • Taneja, S., MacGregor, J., Markus, S., Ha, S., Mohr, I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci U S A 2001, 98(15): 8804-8.
    • (2001) Proc Natl Acad Sci U S A , vol.98 , Issue.15 , pp. 8804-8808
    • Taneja, S.1    MacGregor, J.2    Markus, S.3    Ha, S.4    Mohr, I.5
  • 23
    • 0035036952 scopus 로고    scopus 로고
    • A herpes simplex virus type 1 gamma 34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals
    • Mohr, I., Sternberg, D., Ward, S., Leib, D., Mulvey, M., Gluzman, Y. A herpes simplex virus type 1 gamma 34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001, 75(11): 5189-96.
    • (2001) J Virol , vol.75 , Issue.11 , pp. 5189-5196
    • Mohr, I.1    Sternberg, D.2    Ward, S.3    Leib, D.4    Mulvey, M.5    Gluzman, Y.6
  • 24
    • 84863208397 scopus 로고    scopus 로고
    • Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope
    • Raafat, N., Sadowski-Cron, C., Mengus, C., Heberer, M., Spagnoli, G.C., Zajac, P. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope. Int J Cancer 2012, 131(5): E659-69.
    • (2012) Int J Cancer , vol.131 , Issue.5 , pp. E659-E669
    • Raafat, N.1    Sadowski-Cron, C.2    Mengus, C.3    Heberer, M.4    Spagnoli, G.C.5    Zajac, P.6
  • 25
  • 26
    • 2342641580 scopus 로고    scopus 로고
    • Targets and mechanisms for the regulation of translation in malignant transformation
    • Clemens, M.J. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004, 23(18): 3180-8.
    • (2004) Oncogene , vol.23 , Issue.18 , pp. 3180-3188
    • Clemens, M.J.1
  • 27
    • 84875225339 scopus 로고    scopus 로고
    • Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
    • Heo, J., Reid, T., Ruo, L. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013, 19(3): 329-36.
    • (2013) Nat Med , vol.19 , Issue.3 , pp. 329-336
    • Heo, J.1    Reid, T.2    Ruo, L.3
  • 28
    • 84940824279 scopus 로고    scopus 로고
    • Oncolytic viruses: A new class of immunotherapy drugs
    • Kaufman, H.L., Kohlhapp, F.J., Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015, 14(9): 642-62.
    • (2015) Nat Rev Drug Discov , vol.14 , Issue.9 , pp. 642-662
    • Kaufman, H.L.1    Kohlhapp, F.J.2    Zloza, A.3
  • 29
    • 84863553090 scopus 로고    scopus 로고
    • Targeted and armed oncolytic poxviruses for cancer: The lead example of JX-594
    • Breitbach, C.J., Thorne, S.H., Bell, J.C., Kirn, D.H. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Curr Pharm Biotechnol 2012, 13(9): 1768-72.
    • (2012) Curr Pharm Biotechnol , vol.13 , Issue.9 , pp. 1768-1772
    • Breitbach, C.J.1    Thorne, S.H.2    Bell, J.C.3    Kirn, D.H.4
  • 30
    • 0034294865 scopus 로고    scopus 로고
    • Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colonystimulating factor
    • Toda, M., Martuza, R.L., Rabkin, S.D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colonystimulating factor. Mol Ther 2000, 2(4): 324-9.
    • (2000) Mol Ther , vol.2 , Issue.4 , pp. 324-329
    • Toda, M.1    Martuza, R.L.2    Rabkin, S.D.3
  • 31
    • 73349133717 scopus 로고    scopus 로고
    • Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma
    • Senzer, N.N., Kaufman, H.L., Amatruda, T. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009, 27(34): 5763-71.
    • (2009) J Clin Oncol , vol.27 , Issue.34 , pp. 5763-5771
    • Senzer, N.N.1    Kaufman, H.L.2    Amatruda, T.3
  • 32
    • 84933586864 scopus 로고    scopus 로고
    • Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
    • Andtbacka, R.H., Kaufman, H.L., Collichio, F. et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 2015, 33(25): 2780-8.
    • (2015) J Clin Oncol , vol.33 , Issue.25 , pp. 2780-2788
    • Andtbacka, R.H.1    Kaufman, H.L.2    Collichio, F.3
  • 33
    • 0033998594 scopus 로고    scopus 로고
    • Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor
    • Spitler, L.E., Grossbard, M.L., Ernstoff, M.S., Silver, G., Jacobs, M., Hayes, F.A., Soong, S.J. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000, 18(8): 1614-21.
    • (2000) J Clin Oncol , vol.18 , Issue.8 , pp. 1614-1621
    • Spitler, L.E.1    Grossbard, M.L.2    Ernstoff, M.S.3    Silver, G.4    Jacobs, M.5    Hayes, F.A.6    Soong, S.J.7
  • 34
    • 84936821506 scopus 로고    scopus 로고
    • Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma
    • (May 29-June 2, Chicago) Abst 9063
    • Puzanov, I., Milhem, M.M., Andtbacka, R.H. et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. 51st Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Chicago) 2015, Abst 9063.
    • (2015) 51st Annu Meet Am Soc Clin Oncol (ASCO)
    • Puzanov, I.1    Milhem, M.M.2    Andtbacka, R.H.3
  • 35
    • 84944806473 scopus 로고    scopus 로고
    • Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade
    • (April 18-22, Philadelphia) Abst 258
    • Piasecki, J., Le, T., Ponce, R., Beers, C. Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade. 106th Annu Meet Am Assoc Cancer Res (AACR) (April 18-22, Philadelphia) 2015, Abst 258.
    • (2015) 106th Annu Meet Am Assoc Cancer Res (AACR)
    • Piasecki, J.1    Le, T.2    Ponce, R.3    Beers, C.4
  • 36
    • 84857815877 scopus 로고    scopus 로고
    • Immunologic correlates of the abscopal effect in a patient with melanoma
    • Postow, M.A., Callahan, M.K., Barker, C.A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366(10): 925-31.
    • (2012) N Engl J Med , vol.366 , Issue.10 , pp. 925-931
    • Postow, M.A.1    Callahan, M.K.2    Barker, C.A.3
  • 37
    • 84865782617 scopus 로고    scopus 로고
    • Optimizing cancer treatments to induce an acute immune response: Radiation abscopal effects, PAMPs, and DAMPs
    • Ludgate, C.M. Optimizing cancer treatments to induce an acute immune response: radiation Abscopal effects, PAMPs, and DAMPs. Clin Cancer Res 2012, 18(17): 4522-5.
    • (2012) Clin Cancer Res , vol.18 , Issue.17 , pp. 4522-4525
    • Ludgate, C.M.1
  • 38
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
    • Wolchok, J.D., Hoos, A., O'Day, S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23): 7412-20.
    • (2009) Clin Cancer Res , vol.15 , Issue.23 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3
  • 39
    • 84944741733 scopus 로고    scopus 로고
    • Cell substrates for the production of vaccines for human use
    • 4th ed. Council of Europe: Strasbourg
    • European Directorate for the Quality of Medicines. Cell substrates for the production of vaccines for human use. In:Vol. European Pharmacopoeia 4th ed. Council of Europe: Strasbourg 2002
    • (2002) European Pharmacopoeia
  • 40
    • 84855519656 scopus 로고    scopus 로고
    • Tests for extraneous agents in viral vaccines for human use
    • 4th ed. Council of Europe: Strasbourg
    • European Directorate for the Quality of Medicines. Tests for extraneous agents in viral vaccines for human use. In:Vol. European Pharmacopoeia 4th ed. Council of Europe: Strasbourg 2002
    • (2002) European Pharmacopoeia


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.